Lactobacillus fermentum ME-3 - An antimicrobial and antioxidative probiotic

Microbial Ecology in Health and Disease

Volumn 21, Issue 1, 2009, Pages 1-27

  Mikelsaar, Marika ^a,b   Zilmer, Mihkel ^a  

^a UNIVERSITY OF TARTU   (Estonia)

^b NONE   (Estonia)

Author keywords

Animal experiments; Antimicrobial activity; Antioxidative activity; Atherosclerosis; Atopic dermatitis; Blood lipids; Cerebral stroke; Enteric infections; Food supplements; Functional food; Glutathione; Human clinical trials; Inflammation; Intestinal microbiota

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFOXITIN; COTRIMOXAZOLE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DSM 14241; GLUTATHIONE; LEPTIN; LOW DENSITY LIPOPROTEIN; METRONIDAZOLE; OFLOXACIN; PLACEBO; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROLOX C; UNCLASSIFIED DRUG;

ACID TOLERANCE; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; ATOPIC DERMATITIS; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERIUM CULTURE; BILE; CELL LYSATE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI INFECTION; ESTONIA; EVIDENCE BASED PRACTICE; FUNCTIONAL FOOD; GASTROINTESTINAL INFECTION; GLUTATHIONE METABOLISM; HEALTH PROMOTION; HELICOBACTER INFECTION; HOST; HUMAN; IN VITRO STUDY; INTESTINE FLORA; LABORATORY TEST; LACTOBACILLUS FERMENTUM; LIVER GRANULOMA; MEDICAL SCHOOL; MICROBIAL DIVERSITY; MOLECULAR TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PEPTIC ULCER; PRIORITY JOURNAL; PYELONEPHRITIS; REVIEW; RISK ASSESSMENT; RUSSIAN FEDERATION; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SPLEEN TUMOR; STROKE; TURNOVER TIME; UNITED STATES; WORLD HEALTH ORGANIZATION;

ANIMALIA; LACTOBACILLUS; LACTOBACILLUS FERMENTUM; MUS; SALMONELLA TYPHIMURIUM;

EID: 67651149531     PISSN: 0891060X     EISSN: 16512235     Source Type: Journal    
DOI: 10.1080/08910600902815561     Document Type: Review

References (185)

1. Mackie RI. Mutualistic fermentative digestion in the gastrointestinal tract: diversity and evolution. Integ Comp Biol. 2002;42:319-26.
2. McFarland LV. Normal flora: diversity and functions. Microb Ecol Health Dis. 2000;12:193-218.
3. Dubos R, Schaedler RW. Some biological effects of the digestive flora. Am J Med Sci. 1962;244:265-71.
4. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-33.
5. Savage DC. The normal human microflora composition. In: Grubb R, Midtvedt T, Norin E. editors. The regulatory and protective role of the normal microflora. New York: N-Stockton Press; 1989. p. 3-18.
6. Bhat P, Albert MJ, Rajan D, Ponniah J, Mathan VI, Baker SJ. Bacterial flora of the jejunum: a comparison of luminal aspirate and mucosal biopsy. J Med Microbiol. 1980;13: 247-56.
7. Croucher SC, Houston AP, Bayliss CE, Turner RJ. Bacterial populations associated with different regions of the human colon wall. Appl Environ Microbiol. 1983;45:1025-33.
8. Mikelsaar ME, Tjuri ME, Valjaots ME, Lencner AA. [Anaerobic lumen and mucosal microflora of the gastrointestinal tract.] Nahrung 1984;28:727-33 (in German).
9. Mikelsaar M, Turi M, Lencner H, Kolts K, Kirch R, Lencner A. Interrelations between mucosal and luminal microflora of gastrointestine. Nahrung 1987;31:449-56, 637-8.
10. Zoetendal EG, von Wright A, Vilpponen-Salmela T, BenAmor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol. 2002;68: 3401-7.
11. Nielsen DS, Moller PL, Rosenfeldt V, Paerregaard A, Michaelsen KF, Jakobsen M. Case study of the distribution of mucosa-associated Bifidobacterium species, Lactobacillus species, and other lactic acid bacteria in the human colon. Appl Environ Microbiol. 2003;69:7545-8.
12. Lepage P, Seksik P, Sutren M, de la Cochetiere MF, Jian R, Marteau P, et al. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis. 2005;11:473-80.
13. van der Waaij LA, Harmsen HJ, Madjipour M, Kroese FG, Zwiers M, van Dullemen HM, et al. Bacterial population analysis of human colon and terminal ileum biopsies with
14. rRNA-based fluorescent probes: commensal bacteria live in suspension and have no direct contact with epithelial cells. Inflamm Bowel Dis. 2005;11:865-71.
15. Mikelsaar M, Mandar R. Development of individual lactic acid microflora in the human microbial ecosystem. In: Salminen S, von Wright A. editors. Lactic acid bacteria. New York: Marcel Dekker; 1993. p. 237-93.
16. Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol. 1998; 64:3854-9.
17. Holdeman LV, Good IJ, Moore WE. Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. Appl Environ Microbiol. 1976;31:359-75.
18. Bochkov IA, Lizko NN, Semina NA, Borunov NL, Iurko LP. [Peculiarities of cosmonauts faecal flora.] Aviakosm Ekolog Med 1998;32:25-8 (in Russian).
19. Finegold SM, Sutter VL, Sugihara PT, Elder HA, Lehmann SM, Phillips RL. Fecal microbial flora in Seventh Day Adventist populations and control subjects. Am J Clin Nutr. 1977;30:1781-92.
20. Bry L, Falk PG, Midtvedt T, Gordon JI. A model of hostmicrobial interactions in an open mammalian ecosystem. Science. 1996;273:1380-3.
21. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-8.
22. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA. 2008;105:2117-22.
23. Zoetendal EG, Akkermans AD, Akkermans-van der Vliet VM, De Visser JA, De Vos WM. The host genotype affects the bacterial community in the human gastrointestinal tract. Microb Ecol Health Dis. 2001;13:129-34.
24. Mikelsaar M, Mandar R, Sepp E. Lactic acid microflora in the human microbial ecosystem and its development. In: Lactic acid bacteria. New York: Marcel Dekker; 1998. p. 279-342.
25. Van de Merwe JP, Stegeman JH, Hazenberg MP. The resident faecal flora is determined by genetic characteristics of the host. Implications for Crohn's disease? Antonie Van Leeuwenhoek. 1983;49:119-24.
26. Apperloo-Renkema HZ, Jagt TG, Tonk RH, van der Waaij D. Healthy individuals possess circulating antibodies against their indigenous faecal microflora as well as against allogenous faecal microflora: an immunomorphometrical study. Epidemiol Infect. 1993;111:273-85.
27. Kimura K, McCartney AL, McConnell MA, Tannock GW Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl Environ Microbiol. 1997;63:3394-8.
28. Egert M, De Graaf AA, Smidt H, De Vos WM, Venema K. Beyond diversity: functional microbiomics of the human colon. Trends Microbiol. 2006;14:86-91.
29. McFarland LV. Beneficial microbes: health or hazard? Eur J Gastroenterol Hepatol. 2000;12:1069-71.
30. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688-93.
31. Tannock GW. A special fondness for lactobacilli. Appl Environ Microbiol. 2004;70:3189-94.
32. van der Waaij D, Berghuis JM. Determination of the colonization resistance of the digestive tract of individual mice. J Hyg (Lond). 1974;72:379-87.
33. Naaber P, Mikelsaar M. Interactions between lactobacilli and antibiotic-associated diarrhea. In: Laskin AI, Bennett JW, Gadd GM. editors. Advances in applied microbiology. vol 54. New York: Elsevier; 2004. p. 231-60.
34. Backhed F, Ley RF, Sonnenberg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-20.
35. Banasaz M, Alam M, Norin E, Midtvedt T. Gender, age and microbial status influence upon intestinal cell kinetics in a compartmentalized manner: an experimental study in germfree and conventional rats. Microb Ecol Health Dis. 2000; 12:208-18.
36. Mikelsaar M. Evaluation of the gastrointestinal microbial ecosystem in health and disease. Dis Med Univ Tartuensis, Tartu, 1992.
37. Sepp E, Naaber P, Voor T, Mikelsaar M, Bjorksten B. Development of intestinal microflora during the first month of life in Estonian and Swedish infants. Microb Ecol Health Dis. 2000;12:/22-6.
38. Mikelsaar M, Siigur U, Lenzner A. Evaluation of the quantitative composition of fecal microflora. Laboratornoje Delo. 1990;5:62-6.
39. Sepp E, Julge K, Vasar M, Naaber P, Bjorksten B, Mikelsaar M. Intestinal microflora of Estonian and Swedish infants. Acta Paediatr. 1997;86:956-61.
40. Sepp E, Julge K, Mikelsaar M, Bjorksten B. Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy. 2005;35:1141-6.
41. Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol. 2001;108:516-20.
42. Franks AH, Harmsen HJ, Raangs GC, Jansen GJ, Schut F, Welling GW. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol. 1998;64:3336-5.
43. Zoetendal EG, Vaughan EE, de Vos WM. A microbial world within us. Mol Microbiol. 2006;59:1639-50.
44. Rajilic-Stojanovic M, Smidt H, de Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol. 2007;9:2125-36.
45. Ben-Amor K, Heilig H, Smidt H, Vaughan EE, Abee T, de Vos WM. Genetic diversity of viable, injured, and dead fecal bacteria assessed by fluorescence-activated cell sorting and 16S rRNA gene analysis. Appl Environ Microbiol. 2005;71: 4679-89.
46. Midtvedt T, Bjorneklett A, Carlstedt-Duke B, Gustafsson BE, Hoverstad T, Lingaas E, et al. The influence of antibiotics upon microflora-associated characteristics in man and mammals. Prog Clin Biol Res. 1985;181:241-.
47. Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosystem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev. 1998;62:1157-70.
48. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76.
49. Tamm A, Siigur U, Mikelsaar M, Vija M. Output of bacterial metabolites as a diagnostic means. Nahrung. 1987;31: 485-92.
50. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol. 2006;17:204-10.
51. De Vos WM, Bron PA, Kleerebezem M. Post-genomics of lactic acid bacteria and other food-grade bacteria to discover gut functionality. Curr Opin Biotechnol. 2004;15:86-93.
52. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JL. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA. 2005;102:11070-5.
53. Sonnenburg JL, Xu J, Leip DD, Chen CH, Westover BP, Weatherford J, et al. Glycan foraging in vivo by an intestineadapted bacterial symbiont. Science. 2005;307:1955-9.
54. Lay C, Rigottier-Gois L, Holmstrom K, Rajilic M, Vaughan EE, de Vos WM, et al. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol. 2005;71:4153-5.
55. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-8.
56. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444: 1027-31.
57. ILSI Europe. Scientific concepts of functional foods in Europe: consensus document. Br JNutr. 1999;81:1S-27S.
58. Strachan DP, Golding J, Anderson HR. Regional variations in wheezing illness in British children: effect of migration during early childhood. J Epidemiol Community Health. 1990;44:231-6.
59. Holt PG, Macaubas C, Prescott SL, Sly PD. Microbial stimulation as an aetiologic factor in atopic disease. Allergy. 1999;54:12-6.
60. Adlerberth I. The establishment of normal intestinal microflora in the newborn infants. PhD Dissertation, Göteborg, 1996.
61. Bennet R, Eriksson M, Nord CE, Zetterstrom R. Suppression of aerobic and anaerobic fecal flora in newborns receiving parenteral gentamicin and ampicillin. Acta Paediatr Scand. 1982;71:559-62.
62. Stsepetova J, Sepp E, Julge K, Vaughan E, Mikelsaar M, de Vos WM. Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial communities are characteristic of 5-year-old allergic children. FEMS Immunol Med Microbiol. 2007;51:260-9.
63. Sepp E, Voor T, Julge K, Lõivukene K, Björkstén B, Mikelsaar M. Is intestinal microbiota bound up with changing lifestyle? In: Mendez-Vilas A, ed. Modern multidisciplinary applied microbiology: exploiting microbes and their interactions. Weinheim, Germany: Wiley-VCH Verlag, 2006:708-12.
64. Björkstén B, Graninger G, Jacobsson Ekman G. New ideas in asthma and allergy research: creating a multidisciplinary graduate school. J Clin Invest. 2003;112:816-20.
65. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003; 36:223-7.
66. Kirjavainen PV, Apostolou E, Arvola T, Salminen SJ, Gibson GR, Isolauri E. Characterizing the composition of intestinal microflora as a prospective treatment target in infant allergic disease. FEMS Immunol Med Microbiol. 2001;32:1-7.
67. Food Agriculture Organization: Guidelines for the evaluation of probiotics in food. Available at: http://www.who.int/ foodsafety/fs-management/ en/probiotic-guidelines.pdf
68. Mercenier A, Lenoir-Wijnkoop I, Sanders ME. Physiological and functional properties of probiotics. Bull Int Dairy Fed. 2008;429:2-6.
69. Rijkers GT, Watzl B, Rabot S, Rafter J, Antoine JM, Haller D, et al. ILSI Europe Workshop in association with the International Dairy Federation. Guidance for assessing the probiotics beneficial effects: how to fill GAP. 22-24 May 2008, Montreaux, Switzerland.
70. Reid G, Kim SO, Kohler GA. Selecting, testing and understanding probiotic microorganisms. FEMS Immunol Med Microbiol. 2006;46:149-57.
71. Lu L, Walker WA. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. Am J Clin Nutr. 2001;73:1124S-30S.
72. Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Curr Issues Intest Microbiol. 2006;7:73-89.
73. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr. 2001;73:430S-6S.
74. Salminen S. Human studies on probiotics: aspects of scientific documentation. Scand J Nutr. 2001;45:8-12.
75. Charteris WP, Kelly PM, Morelli L, Collins JK. Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract. J Appl Microbiol. 1998;84: 759-68.
76. Ross RP, Desmond C, Fitzgerald GF, Stanton C. Overcoming the technological hurdles in the development of probiotic foods. J Appl Microbiol. 2005;98:1410-7.
77. Klaver FA, van der Meer R. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl Environ Microbiol. 1993;59:1120-.
78. Gibson GR. Dietary modulation of the human gut microflora using prebiotics. Br J Nutr. 1998;80:S209-12.
79. Wang KY, Li SN, Liu CS, Perng DS, Su YC, Wu DC, et al. Effects of ingesting Lactobacillus- and Bifidobacteriumcontaining yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004;80:737-1.
80. Anderson JW, Gilliland SE. Effect of fermented milk (yoghurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr. 1999;18:43-50.
81. Cruchet S, Obregon MC, Salazar G, Diaz E, Gotteland M. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children. Nutrition. 2003;19:716-21.
82. Sakamoto I, Igarashi M, Kimura K, Takagi A, Miwa T, Koga Y Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother. 2001;47:709-10.
83. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol. 2003;17:655-9.
84. De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol. 2007;292: G358-68.
85. Turchet P, Laurenzano M, Auboiron S, Antoine JM. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study. J Nutr Health Aging. 2003;7:75-7.
86. Pereg D, Kimhi O, Tirosh A, Orr N, Kayouf R, Lishner M. The effect of fermented yogurt on the prevention of diarrhea in a healthy adult population. Am J Infect Control. 2005;33: 122-5.
87. Tiollier E, Chennaoui M, Gomez-Merino D, Drogou C, Filaire E, Guezennec CY Effect of a probiotics supplementation on respiratory infections and immune and hormonal parameters during intense military training. Mil Med. 2007; 172:1006-11.
88. Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol. 2005;16:433-8.
89. Hilton E, Kolakowski P, Singer C, Smith M. Efficacy of Lactobacillus GG as a diarrheal preventive in travelers. J Travel Med. 1997;4:41-3.
90. Szajewska H, Kotowska M, Mrukowicz JZ, Armanska M, Mikolajczyk W Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr. 2001;138: 361-5.
91. Viljanen M, Kuitunen M, Haahtela T, Juntunen-Backman K, Korpela R, Savilahti E. Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol. 2005;16:65-71.
92. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001;357:1076-9.
93. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007;119:1019-21.
94. Di Caro S, Tao H, Grillo A, Franceschi F, Elia C, Zocco MA, et al. Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis. Eur J Gastroenterol Hepatol. 2005;17:951-60.
95. Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Moller PL, Tvede M, et al. Effect of probiotic Lactobacillus strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. Pediatr Infect Dis J. 2002;21:417-9.
96. Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr. 2001; 20(2 Suppl):149-56.
97. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74:123-7.
98. Linsalata M, Russo F, Berloco P, Caruso ML, Matteo GD, Cifone MG, et al. The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa. Helicobacter. 2004;9:165-72.
99. Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol. 2004;70:1176-81.
100. Casas IA, Dobrogosz WJ. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis. 2000;12:247-85.
101. Kullisaar T, Songisepp E, Mikelsaar M, Zilmer K, Vihalemm T, Zilmer M. Antioxidative probiotic fermented goats' milk decreases oxidative stress-mediated atherogenicity in human subjects. Br J Nutr. 2003;90:449-56.
102. Songisepp E, Kals J, Kullisaar T, Mandar R, Hutt P, Zilmer M, et al. Evaluation of the functional efficacy of an antioxidative probiotic in healthy volunteers. Nutr J. 2005; 4:22.
103. Kaur S, Kullisaar T, Mikelsaar M, Eisen M, Rehema A, Vihalemm T, et al. Successful management of mild atopic dermatitis in adults with probiotics and emollients. Cent Eur J Med. 2008;3:215-20.
104. Lencner AA, Lencner CP, Mikelsaar ME, Tjuri ME, Toom MA, Valjaots ME, et al. [The quantitative composition of the intestinal lactoflora before and after space flights of different lengths.] Nahrung 1984;28:607-13 (in German).
105. Lencner A, Lencner H, Brilis V, Brilene T, Mikelsaar M, Turi M. [The defense function of the digestive tract lactoflora.] Nahrung 1987;31:405-11 (in German).
106. Mikelsaar MH, Annuk A, Shchepetova J, Mändar R, Sepp E, Bjorksten B. Intestinal lactobacilli of Estonian and Swedish children. Microb Ecol Health Dis. 2002;14:75-80.
107. Kaizu H, Sasaki M, Nakajima H, Suzuki Y. Effect of antioxidative lactic acid bacteria on rats fed a diet deficient in vitamin E. J Dairy Sci. 1993;76:2493-9.
108. Parik T, Allikmets K, Teesalu R, Zilmer M. Oxidative stress and hyperinsulinaemia in essential hypertension: different facets of increased risk. J Hypertens. 1996;14:407-10.
109. Kaur S, Zilmer M, Eisen M, Kullisaar T, Rehema A, Vihalemm T Patients with allergic and irritant contact dermatitis are characterized by striking change of iron and oxidized glutathione status in nonlesional area of the skin. J Invest Dermatol. 2001;116:886-90.
110. Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, et al. The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res. 2001;26:353-61.
111. Mikelsaar M, Kullisaar T, Zilmer M. Antagonistic and antioxidative activity of lactobacilli and survival in oxidative milieu. Am J Clin Nutr. 2001;73:495S.
112. Woodmansey EJ, McMurdo ME, Macfarlane GT, Macfar-lane S. Comparison of compositions and metabolic activities of fecal microbiotas in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol. 2004;70:6113-22.
113. Silvi S, Verdenelli MC, Orpianesi C, Cresci A. EU project Crownalife: functional foods, gut microflora and healthy ageing. Isolation and identification of lactobacillus and Bifidobacterium strains from faecal samples of elderly subjects for a possible probiotic use in functional foods. J Food Engin. 2003;56:195-200.
114. Pereira DI, Gibson GR. Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol. 2002;68:4689-93.
115. Vassos D, Maipa V, Voidarou C, Alexopoulos A, Bezirtzoglou E. Development of human lactic acid (LAB) gastrointestinal microbiota in a Greek rural population. Cent Eur J Biol. 2008;3:55-60.
116. Matsuguchi T, Takagi A, Matsuzaki T, Nagaoka M, Ishikawa K, Yokokura T, et al. Lipoteichoic acids from Lactobacillus strains elicit strong tumor necrosis factor alpha-inducing activities in macrophages through Toll-like receptor 2. Clin Diagn Lab Immunol. 2003;10:259-66.
117. Vinderola CG, Medici M, Perdigon G. Relationship between interaction sites in the gut, hydrophobicity, mucosal immunomodulating capacities and cell wall protein profiles in indigenous and exogenous bacteria. J Appl Microbiol. 2004;96:230-3.
118. Midtvedt AC, Midtvedt T Production of short chain fatty acids by the intestinal microflora during the first 2 years of human life. J Pediatr Gastroenterol Nutr. 1992;15: 395-03.
119. Songisepp E. Evaluation of technological and functional properties of the new probiotic Lactobacillus fermentum ME-3. Diss Med Univ Tartuensis, 2005.
120. .Štšepetova J, Sepp E, Hütt P, Mikelsaar M. Estimation of lactobacilli, enterococci and bifidobacteria in faecal samples by quantitative bacteriology and FISH. Microecol Therapy. 2002;29:51-9.
121. Mikelsaar M, Zilmer M, Kullisaar M, Annuk H, Songisepp E. Strain of microorganism Lactobacillus fermentum ME-3 as novel antimicrobial and antioxidative probiotic. Patent application no. P200100356 29.06.2001.
122. Annuk H, Shchepetova J, Kullisaar T, Songisepp E, Zilmer M, Mikelsaar M. Characterization of intestinal lactobacilli as putative probiotic candidates. J Appl Microbiol. 2003;94: 403-12.
123. Kandler O, Weiss N. Regular gram positive nonsporing rods. In: Sneath PHA, Mair NS, Sharp MS, Holt JG, eds. Bergey's manual of systematic bacteriology, Vol 2. Baltimore: Williams & Wilkins, 1986:1208-34.
124. Smidt I, Stsepetova J, Hütt P, Sepp E, Mikelsaar M. Evaluation of biogenic amines in urine after synbiotic consumption. Probiotics, Synbiotics and Functional Foods: Scientific and Clinical Aspects, 15-16 May 2007, Peterburg, Russia: Medline-Medina, 2007;1-2:A13-A14.
125. Songisepp E, Mikelsaar M, Rätsep M, Zilmer M, Hütt P, Utt M, et al. Isolated microorganism strain Lactobacillus plantarum Tensia DSM 21380 as antimicrobial and antihypertensive probiotic, food product and composition comprising said microorganism and use of said microorganism for production of antihypertensive medicine and method for suppressing non-starter lactobacilli in food product. Estonian Patent Office. 13.05.2008. P200800026.
126. Bover-Cid S, Holzapfel WH. Improved screening procedure for biogenic amine production by lactic acid bacteria. Int J Food Microbiol. 1999;53:/3341.
127. Kidata M, Igarashi K, Hirose S, Kitagawa H. Inhibition by polyamines of lipid peroxide formation in rat liver microsomes. Biochem Biophys Res Commun. 1979;87:388-94.
128. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol. 2003;94:449-55.
129. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol. 1999;65:351-.
130. Cesana BM. Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al.(2000). Clin Endocrinol. 2001;55: 695-7.
131. Liener IE, Sharon N, Goldstein IJ. The lectins. Properties, functions, and applications in biology and medicine. Orlando, FL: Academic Press; 1986.
132. Onyshchenko AM, Korobkova KS, Kovalenko NK, Kasumova SO, Skrypal IH. [The role of the carbohydrate composition of the glycocalyx in some species of lactobacilli in the manifestation of their adhesive properties.] Mikrobiol Z 1999;61:22-8 (in Ukrainian).
133. Annuk H, Hynes SO, Hirmo S, Mikelsaar M, Wadstrom T Characterisation and differentiation of lactobacilli by lectin typing. J Med Microbiol. 2001;50:1069-74.
134. Karkkainen UM, Ikaheimo R, Katila ML, Siitonen A. Recurrence of urinary tract infections in adult patients with community-acquired pyelonephritis caused by E. coli: a 1-year follow-up. Scand J Infect Dis. 2000;32:495-9.
135. Ouwehand AC, Derrien M, de Vos W, Tiihonen K, Rautonen N. Prebiotics and other microbial substrates for gut functionality. Curr Opin Biotechnol. 2005;16:212-7.
136. Annuk H, Hirmo S, Turi E, Mikelsaar M, Arak E, Wadstrom T. Effect on cell surface hydrophobicity and susceptibility of Helicobacter pylori to medicinal plant extracts. FEMS Microbiol Lett. 1999;172:41-5.
137. Songisepp E, Kullisaar T, Hutt P, Elias P, Brilene T, Zilmer M, et al. A new probiotic cheese with antioxidative and antimicrobial activity. J Dairy Sci. 2004;87:2017-23.
138. Annuk H. Selection of medicinal plants and intestinal lactobacilli as antimicrobial components for functional foods. Diss Med Univ Tartuensis, Tartu, 2002.
139. Hütt P, Shchepetova J, Lõivukene K, Kullisaar T, Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl Microbiol. 2006;100:1324-32.
140. Hütt P, Lõivukene K, Utt M. Antagonistic activity of probiotic Lactobacillus fermentum ME-3 against H. pylori strains. 6th International Workshop on Pathogenesis and Host Response in Helicobacter Infections, 23-26 June 2004, Helsingor, Denmark.
141. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006;23: 1077-86.
142. Marchand J, Vandenplas Y. Micro-organisms administered in the benefit of the host: myths and facts. Eur J Gastroenterol Hepatol. 2000;12:1077-88.
143. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis. 2006;42:35-44.
144. Vankerckhoven V, Huys G, Vancanneyt M, Vael C, Klare I, Romond MB, et al. Biosafety assessment of probiotics used for human consumption: recommendations from the EU-PROSAFE project. Trends Food Sci Technol. 2008;19: 102-14.
145. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. New York: Oxford University Press; 1999.
146. Sies H. Oxidative stress: oxidants and antioxidants. London, Academic Press, 1991.
147. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-78.
148. Kals J, Kampus P, Kals M, Zilmer K, Kullisaar T, Teesalu R, et al. Impact of oxidative stress on arterial elasticity in patients with atherosclerosis. Am J Hypertens. 2006;19: 902-8.
149. Stojiljkovic V, Todorovic A, Radlovic N, Pejic S, Mladenovic M, Kasapovic J, et al. Antioxidant enzymes, glutathione and lipid peroxidation in peripheral blood of children affected by coeliac disease. Ann Clin Biochem. 2007;44(Pt 6):537-3.
150. Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis. 2008;14:794-802.
151. Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. Curr Med Chem. 2007; 14:339-51.
152. Suzuki M, Kamei M, Itabe H, Yoneda K, Bando H, Kume N, et al. Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis. 2007;13:772-8.
153. Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA. Alzheimer disease pathology as a host response. J Neuro-pathol Exp Neurol. 2008;67:523-31.
154. Vincent HK, Innes KE, Vincent KR. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obes Metab. 2007;9:813-39.
155. Mensink RP, Aro A, Den Hond E, German JB, Griffin BA, ten Meer HU, et al. PASSCLAIM - Diet-related cardiovascular disease. EurJNutr. 2003;42(Suppl 1):I6-27.
156. Vaughan EE, Heilig HG, Ben-Amor K, de Vos WM. Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches. FEMS Microbiol Rev. 2005;29:477-90.
157. Kullisaar T, Zilmer M, Mikelsaar M, Vihalemm T, Annuk H, Kairane C, et al. Two antioxidative lactobacilli strains as promising probiotics. Int J Food Microbiol. 2002;72: 215-24.
158. Mikelsaar M, Zilmer M. In: Schiavi C, editor. Probiotics series (4) Probiotics biotherapeutics & health: microbial, biochemical and probiotical history (ME-3). Novara, Italy: Mofin Alce; 2005. p. 114-37.
159. Kullisaar T, Songisepp E, Aunapuu M, Kilk K, Arend A, Mikelsaar M, et al. Complete glutathione system in probiotic L. fermentum ME-3. Appl Biochem Microbiol 2009; 45 (in press).
160. Jarvenpaa S, Tahvonen RL, Ouwehand AC, Sandell M, Jarvenpaa E, Salminen S. A probiotic, Lactobacillus fermentum ME-3, has antioxidative capacity in soft cheese spreads with different fats. J Dairy Sci. 2007;90:3171-7.
161. Teemu H, Seppo S, Jussi M, Raija T, Kalle L. Reversible surface binding of cadmium and lead by lactic acid and bifidobacteria. Int J Food Microbiol. 2008;125:170-5.
162. Truusalu K, Naaber P, Kullisaar T, Tamm H, Mikelsaar R-H, Zilmer K, et al. The influence of antibacterial and antioxidative probiotic lactobacilli on gut mucosa in mouse model of Salmonella infection. Microb Ecol Health Dis. 2004;16:180-7.
163. Kullisaar T, Mikelsaar M, Kaur S, Songisepp E, Zilmer K, Hutt P, et al. Probiotics, oxidative stress and diseases. In: Ćurić D, editor. , ed. Proceedings of the 2008 Joint Central European Congress: 4th Central European Congress on Food and 6th Croatian Congress of Food Technologists, Biotechnologists and Nutritionists, 15-17 May 2008, Cav-tat, Croatia, 2008;1:367-73. ISBN 978-953-6207-87-9.
164. Kullisaar T, Zilmer K, Vihalemm T, Zilmer M. Consumption of antioxidative probiotic probiotic L. fermentum ME-3 and its impact on post-prandial lipid profile in human volunteers. Third Central European Congress on Food, May 2006, Sofia, Bulgaria: p. 208.
165. Truusalu K, Mikelsaar RH, Naaber P, Karki T, Kullisaar T, Zilmer M, et al. Eradication of Salmonella Typhimurium infection in a murine model of typhoid fever with the combination of probiotic Lactobacillus fermentum ME-3 and ofloxacin. BMC Microbiol. 2008;8:132.
166. Igarashi T, Kono Y, Tanaka K. Molecular cloning of manganese catalase from Lactobacillus plantarum. J Biol Chem. 1996;271:29521-.
167. Rochat T, Gratadoux JJ, Gruss A, Corthier G, Maguin E, Langella P, et al. Production of a heterologous nonheme catalase by Lactobacillus casei: an efficient tool for removal of H2O2 and protection of Lactobacillus bulgaricus from oxidative stress in milk. Appl Environ Microbiol. 2006;72: 5143-9.
168. Mikelsaar M, Hutt P, Kullisaar T, Zilmer K, Zilmer M. Double benefit claims for antimicrobial and antioxidative probiotic. MEHD. 2008;20(4):184-88.
169. Mattila-Sandholm T, Blum S, Collins JK, Crittenden R, de Vos W, Dunne C, et al. Probiotics: towards demonstrating efficacy. Trends Food Sci Technol. 1999;10:393-9.
170. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol. 2001;152:735-1.
171. Saulnier DMA, Hutt P, Mikelsaar M, Bosscher D, Gibson G, Kolida S. Effects of a symbiotic on biomarkers of oxidative stress and fecal microbiota in healthy adults: results of a cross-over double-blind placebo controlled trial. Proc Nutr Soc. 2007;66:101A.
172. Mikelsaar M, Zilmer M, Kullisaar T, Annuk H, Songisepp E. Strain of microorganism Lactobacillus fermentum ME-3 as novel antimicrobial and antioxidative probiotic. United States Patent 7, 244, 424 B2. Approved July 17, 2007.
173. Jones DP. Redefining oxidative stress. Antioxid Redox Signal. 2006;8:1865-79.
174. Karelson E, Mahlapuu R, Zilmer M, Soomets U, Bogdanovic N, Langel U. Possible signaling by glutathione and its novel analogue through potent stimulation of fontocortical G proteins in normal aging and in Alzheimer's disease. Ann N Y Acad Sci. 2002;973:537-0.
175. Zilmer M, Soomets U, Rehma A, Langel U. Drug Design Reviews - Online. 2005;2:121-7.
176. Peran L, Sierra S, Comalada M, Lara-Villoslada F, Bailon E, Nieto A, et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr. 2007;97:96-103.
177. de la Asuncion JG, Millan A, Pla R, Bruseghini L, Esteras A, Pallardo FV, et al. Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA. FASEB J. 1996;10:/333-8.
178. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-70.
179. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA. 2008;299:2287-93.
180. Kampus P, Kals J, Ristimae T, Muda P, Ulst K, Zilmer K, et al. Augmentation index and carotid intima-media thickness are differently related to age, C-reactive protein and oxidized low-density lipoprotein. J Hypertens. 2007;25: 819-25.
181. George J. Mechanisms of disease: the evolving role of regulatory T cells in atherosclerosis. Nat Clin Pract Cardi-ovasc Med. 2008;5:531-0.
182. Lopez-Miranda J, Perez-Martinez P, Marin C, Moreno JA, Gomez P, Perez-Jimenez F Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease. Curr Opin Lipidol. 2006;17:132-8.
183. Marsillach J, Camps J, Ferré N, BeltranR, Rull A, Mackness B, et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol. 2009;9:3-10.
184. Elliott WJ. Renovascular hypertension: an update. J Clin Hypertens (Greenwich). 2008;10:522-33.
185. Bhatt DL. Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention. Am J Cardiol. 2008;101(10A):4D-13.